A new heat-based laser therapy from Finnish researchers offers patients with dry age-related macular degeneration three distinct advantages worth understanding. First, the treatment prioritizes prevention over intervention, activating cellular repair mechanisms before irreversible damage occurs—a fundamental departure from current approaches that attempt to reverse existing pathology. Second, the therapy maintains exacting precision, operating within a narrow temperature window of 43-45°C to stimulate autophagy while protecting surrounding tissue from thermal injury. Third, this innovation directly addresses the treatment gap affecting 90% of AMD patients with the dry form, offering hope where few options currently exist. The preventive approach targets retinal pigment epithelium cells before they lose their capacity to support photoreceptors responsible for central vision. For patients and clinicians managing dry AMD, understanding these mechanisms clarifies why this experimental treatment represents a meaningful advancement. Early laboratory results support further clinical investigation into this promising modality.
Read the full article on GMJ Newsroom.
Was this article helpful?
